Replies to post #459510 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I don't see how it would detract. I have two disorders that are not currently covered by trials, so if 2-73 were to be approved there would be data to support off label use.

Seems like a win-win to me.